Exchange & Returns Information
Review Details
(28)
| Drug Type | Original |
|---|---|
| Active Ingredient | TIRZEPATIDE |
| Strength | 7.5MG |
| Manufacturer | ELI LILLY AND COMPANY |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 PEN | $ 305.00 | $ 305.00 |
$ 256.20
Apply MOUN26 (-16%)
You save $ 48.80
|
||
| 2 BOXES - 2 PENS | $ 297.50 |
2% $ 610.00
$ 595.00
|
$ 499.80
Apply MOUN26 (-16%)
You save $ 95.20
|
||
| ★ Best Value 3 BOXES - 3 PENS | $ 291.67 |
4% $ 915.00
$ 875.00
|
$ 735.00
Apply MOUN26 (-16%)
You save $ 140.00
|
Reference information will be available soon.
Mounjaro 7.5mg is a once-weekly GLP-1 and GIP dual receptor agonist injection used to treat type 2 diabetes. Following the 2.5mg initiation phase and 5mg therapeutic baseline, the 7.5mg dose is a step-up in dosage escalation, offering enhanced glycemic control and additional metabolic benefits. While not primarily intended for weight loss or obesity treatment, many patients experience meaningful weight reduction as a secondary effect. This formulation is part of a broader titration strategy that supports gradual therapeutic intensification based on patient tolerability and HbA1c response.
- DIABETES (GLP-1 Receptor Agonists) > Used as a second-line injectable option for type 2 diabetes patients seeking additional glucose control beyond oral therapies. The 7.5mg dose typically follows the initial 5mg therapeutic phase and contributes to greater HbA1c reduction through dual incretin activity. - DIET (Metabolic Weight Control) > Tirzepatide demonstrates consistent and progressive weight reduction across all escalation doses. Although not a weight loss drug per se, its metabolic effects promote meaningful body weight changes in overweight or obese type 2 diabetes patients. - LIFESTYLE-RELATED DISEASES (Obstructive Sleep Apnea – off-label) > Off-label research has shown that tirzepatide can help reduce sleep apnea severity in obese individuals, likely due to its weight-reducing effects. The product is not officially approved for OSA but is sometimes used in dual-targeted regimens for comorbid obesity. - AntiCancer Drugs (Others – metabolic-linked cancer modulation) > Ongoing preclinical and observational studies suggest potential preventive benefits of tirzepatide in obesity-related cancers, such as breast cancer. These findings are early-stage but highlight the compound’s broader implications in chronic disease prevention through metabolic modulation.
Tirzepatide functions as a dual incretin mimetic, simultaneously stimulating GLP-1 and GIP receptors. This leads to enhanced insulin secretion, delayed gastric emptying, and improved glycemic response. Its combined mechanism provides superior HbA1c reduction compared to GLP-1 agonists alone, while also promoting satiety and reducing appetite.
➔ Weekly Subcutaneous Injection (Type 2 Diabetes Indication): - Week 1–4: 2.5 mg SC once weekly (Initiation phase only) - Week 5–8: 5 mg SC once weekly (Standard therapeutic dose) - Week 9+: 7.5 mg SC once weekly (This product) ➔ Further escalation (if tolerated and necessary): - 10 mg → 12.5 mg → 15 mg at 4-week intervals ➔ Maintenance Dose: 5–15 mg SC per week depending on efficacy and tolerability ➔ Maximum Dose: 15 mg per week ➔ Administration Notes: - Inject into abdomen, thigh, or upper arm - Same time weekly, with or without food - If dose is missed: inject within 96 hours, skip if longer ➔ Drug Interactions / Adjustments: - May be combined with metformin, SGLT2 inhibitors, sulfonylureas, or basal insulin - Dose reduction may be needed for insulin or sulfonylureas to prevent hypoglycemia ➔ Special Considerations: - Not for type 1 diabetes or diabetic ketoacidosis - Contraindicated in patients with a history of medullary thyroid carcinoma or MEN2 - Monitor renal function, pancreatitis risk, and diabetic retinopathy in high-risk patients ➔ Off-Label Observations: - May reduce diabetes onset from prediabetes by up to 94% - Studied in obesity-related cancer models and neurodegenerative disease prevention - Supports OSA improvement in obese patients (Zepbound overlap)
Store unused pens in refrigerator (2–8°C) Do not freeze Once in use, pens can be stored at room temperature (below 30°C) for up to 21 days Protect from light and moisture Keep out of reach of children
Common side effects include nausea, vomiting, diarrhea, constipation, and decreased appetite Other transient reactions: fatigue, dizziness, indigestion, injection site irritation Severe risks (rare): pancreatitis, gallbladder disease, kidney issues, or hypersensitivity Hypoglycemia risk increases when combined with insulin or sulfonylureas Consult a physician if side effects are persistent or worsen
I had a quick question about my tracking number, and their CS team responded to my email in under an hour. So efficient!
My package was one of the unlucky few that got seized by customs. I was devastated, thinking I had lost my money and my medication for the month. But I had purchased the shipping insurance. I contacted customer service, sent them a screenshot of the tracking status, and that was it. No hassle, no endless questions. They processed a reshipment the very next day, free of charge. The new package arrived quickly. That small insurance fee turned a potential disaster into a minor inconvenience. I will never place an order without it.
I'm always impressed by the professional and reliable shipping to Canada.
Tuve una pequeña duda sobre mi pedido y el equipo de atención al cliente me respondió por correo electrónico en menos de una hora. Muy eficientes y amables.
My third Mounjaro pen arrived right on schedule. The service has been consistently flawless.
No combo deals available at the moment.
